Acute Myeloid Leukemia: Personalized Treatment Based on FLT3 Mutation

We are studying a new treatment strategy for patients with FLT3-positive AML, using a biomarker to tailor therapy. The goal is to see if this approach improves survival compared to standard treatments.

>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOralInjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Aracytin
Aracytin is a chemotherapy medicine used to treat certain types of cancer, especially leukemia.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Cytarabine
Cytarabine is a chemotherapy substance used to treat certain blood cancers, especially acute leukemias.
Daunorubicin Hydrochloride
Daunorubicin hydrochloride is a cancer-fighting substance used to treat certain blood cancers like leukemia by killing rapidly dividing cancer cells.
Midostaurin
Midostaurin is a targeted cancer substance that blocks proteins driving growth of certain blood cancers, such as FLT3‑mutated acute myeloid leukemia.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Alexan
Ara-Cell
Aracytine

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Azienda Ospedaliera Nazionale Ss Antonio E Biagio E C Arrigo Alessandria
Dipartimento Internistico - SOC EMATOLOGIA
Alessandria, Italy
University Hospital Consorziale Policlinico
Dipartimento dell'Emergenza e dei Trapianti di Organi (D.E.T.O.)- UO EMATOLOGIA
Altamura, Italy
Istituto Tumori Bari Giovanni Paolo II
UO EMATOLOGIA
Bari, Italy
Sponsor: Fondazione Gimema Franco Mandelli Onlus
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.